Singapore markets closed
Straits Times Index
3,306.02 +6.02 (+0.18%) Nikkei
38,596.47 -36.55 (-0.09%) Hang Seng
18,028.52 -306.80 (-1.67%) FTSE 100
8,237.72 -34.74 (-0.42%) Bitcoin USD
64,102.86 -856.53 (-1.32%) CMC Crypto 200
1,331.03 -29.29 (-2.15%)
PCVX Sep 2024 75.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 09:30AM EDT. Market open.
| Previous close | 11.20 |
| Open | 11.20 |
| Bid | 10.90 |
| Ask | 15.00 |
| Strike | 75.00 |
| Expiry date | 2024-09-20 |
| Day's range | 11.20 - 11.20 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
Simply Wall St.We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
GlobeNewswireVaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
© 2024 Yahoo. All rights reserved.